Episode Details
Back to Episodes
Immunotherapy breakthrough for bowel cancer & China’s rapid everyday AI adoption - News (May 6, 2026)
Published 2 weeks, 1 day ago
Description
Please support this podcast by checking out our sponsors:
- Lindy is your ultimate AI assistant that proactively manages your inbox - https://try.lindy.ai/tad
- Consensus: AI for Research. Get a free month - https://get.consensus.app/automated_daily
- Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron
Support The Automated Daily directly:
Buy me a coffee: https://buymeacoffee.com/theautomateddaily
Episode Transcript
Immunotherapy breakthrough for bowel cancer
We’ll start in health, with results that are turning heads in oncology. A UK-led clinical trial tested the immunotherapy drug pembrolizumab before surgery in a specific subtype of stage II to III colorectal cancer—tumors described as MMR-deficient or MSI-high. Early checks suggested many patients had no detectable cancer after treatment and surgery, but the longer follow-up is what really stands out: after a median of about 33 months, none of the participants had relapsed. If this holds up in larger studies, it could change the usual playbook—shifting some patients away from months of post-surgery chemotherapy and toward a faster, more targeted start. Researchers also highlighte
- Lindy is your ultimate AI assistant that proactively manages your inbox - https://try.lindy.ai/tad
- Consensus: AI for Research. Get a free month - https://get.consensus.app/automated_daily
- Invest Like the Pros with StockMVP - https://www.stock-mvp.com/?via=ron
Support The Automated Daily directly:
Buy me a coffee: https://buymeacoffee.com/theautomateddaily
Today's topics:
Immunotherapy breakthrough for bowel cancer - A UK-led NEOPRISM-CRC trial reports unusually durable results using pembrolizumab before surgery in MMR-deficient/MSI-high colorectal cancer, with zero relapses at 33 months. Keywords: immunotherapy, pembrolizumab, ctDNA, AACR 2026, colorectal cancer.
China’s rapid everyday AI adoption - China is normalizing generative and agentic AI at massive scale, with government figures citing over 600 million users and data suggesting Chinese models now consume more tokens weekly than US models. Keywords: China AI, agentic AI, Tencent, Alibaba, Baidu, Huawei chips.
US pre-release AI safety tests - Google, Microsoft, and xAI will voluntarily submit new models to the US Commerce Department’s CAISI for evaluations covering capability, security, and national-security risks—signaling a shift toward more oversight. Keywords: CAISI, AI standards, safety testing, US Commerce, model evaluation.
AI lawsuits: OpenAI and Meta - Two high-stakes legal fights intensify: OpenAI leadership faces a Musk-linked dispute over mission and governance, while authors and major publishers sue Meta over alleged pirated training data for Llama. Keywords: OpenAI lawsuit, Musk, Brockman, Meta Llama, copyright.
AI-driven market shakeups in tech - Investors are reshuffling AI winners: Alphabet nears Nvidia in market value on surging Google Cloud, Micron rallies on memory shortages, and chip-and-server names jump on strong demand signals. Keywords: Alphabet, Nvidia, Google Cloud, Micron, AMD, Super Micro.
China urges ceasefire in Iran war - China calls for an urgent ceasefire in the US–Iran war as shipping disruptions near the Strait of Hormuz rattle energy markets, while Washington signals it may be close to an agreement. Keywords: Strait of Hormuz, ceasefire, Wang Yi, Trump, oil shipments.
Armenia pivots toward the EU - Armenia hosted its first bilateral summit with the EU, signing a connectivity partnership and deepening security cooperation as Yerevan distances itself from Russia after Nagorno-Karabakh. Keywords: Armenia, EU summit, CSTO freeze, connectivity, Azerbaijan tensions.
Episode Transcript
Immunotherapy breakthrough for bowel cancer
We’ll start in health, with results that are turning heads in oncology. A UK-led clinical trial tested the immunotherapy drug pembrolizumab before surgery in a specific subtype of stage II to III colorectal cancer—tumors described as MMR-deficient or MSI-high. Early checks suggested many patients had no detectable cancer after treatment and surgery, but the longer follow-up is what really stands out: after a median of about 33 months, none of the participants had relapsed. If this holds up in larger studies, it could change the usual playbook—shifting some patients away from months of post-surgery chemotherapy and toward a faster, more targeted start. Researchers also highlighte